Akero Therapeutics, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

The submission of this form does not create an attorney-client relationship.

Investigation Details

On October 10, 2023, AKRO announced Efruxifermin (EFX) failed to meet the primary endpoint of fibrosis improvement at 36 weeks in the Phase 2B SYMMETRY trial in NASH patients with compensated cirrhosis. The Company’s President and CEO stated “we set a high bar with the primary endpoint after only 36 weeks of treatment.” Analysts noted that they were surprised at the 36 week miss and the study design may have stretched EFX too far.

Following this news, AKRO’s stock price fell by $30.39 per share, or approximately 63% to close at $18.15 per share.